Madrigal Pharmaceuticals, Inc.
$512.39
$6.35(-1.22%)
Madrigal Pharmaceuticals, Inc.
MDGL
$512.39
$6.35(-1.22%)
Madrigal Pharmaceuticals, Inc.
MDGL
NASDAQ
$512.39
$6.35(-1.22%)
Chart
Upcoming Earnings
Next report date
May 6, 2026
Report period
Q2 2026
EPS Estimate
$-4.14
Revenue Estimate
$301.27M
Key stats
52-Week Range$512.39
$265.00
$615.00
Market capitalization
$11.53BDividend yield (indicated)
0.00%Price to earnings Ratio (TTM)
-39.98Basic EPS (TTM)
$-12.87Net income (TTM)
$-288.28MRevenue (TTM)
$958.40MAvg. volume
345.53KBeta (1Y)
-1.01Employees
528Market capitalization
$11.53BDividend yield (indicated)
0.00%Price to earnings Ratio (TTM)
-39.98Basic EPS (TTM)
$-12.87Net income (TTM)
$-288.28MRevenue (TTM)
$958.40MAvg. volume
345.53KBeta (1Y)
-1.01Employees
528Screener Quick Check
Sign in to check this stock against your screeners
Sign InAbout Madrigal Pharmaceuticals, Inc.
Sector
Healthcare
Industry
Biotechnology
CEO
William J. Sibold
Website
www.madrigalpharma.comHeadquarters
Four Tower Bridge, West Conshohocken, PA, 19428
IPO Date
2007-02-06
Identifiers
ISIN
US5588681057Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates...
Related Stocks
$46.71
1D:
-1.2%
1Y:
67.8%
US60770K1079Healthcare
Mkt Cap
$18.52B
P/E Ratio TTM
-5.6
Revenue TTM
$1.94B
Beta
1.06
Earnings TTM
$-2.82B
Dividend Yield TTM
0.00%
$212.26
1D:
2.0%
1Y:
79.6%
IE00B4Q5ZN47Healthcare
Mkt Cap
$13.32B
P/E Ratio TTM
-34.7
Revenue TTM
$4.27B
Beta
0.23
Earnings TTM
$-356.15M
Dividend Yield TTM
0.00%
Dividend Overview
This company does not pay dividends
Financials
Performance
Margin trends
Debt level and coverage
Earnings
Next: Q2 '26
Actual
Estimate
Performance
Margin trends
Debt level and coverage
Earnings
Next: Q2 '26
Actual
Estimate